Content: Slate Blackcurrant Watermelon Strawberry Orange Banana Apple Emerald Chocolate Marble
Background: Slate Blackcurrant Watermelon Strawberry Orange Banana Apple Emerald Chocolate Marble
Pattern: Blank Waves Notes Sharp Wood Rockface Leather Honey Vertical Triangles

Clinical Advertisement

IBS News

Showing topics posted by Health Reporter and posted in for the last 365 days.

  1. Today
  2. *This Friday* @US_FDA, ACG & like-minded organizations host: Pediatric #InflammatoryBowelDisease (#IBD) Workshop Who: Open to the public When: November 16 Where: FDA White Oak Campus, Silver Spring, MD There is no cost, but registration is required ➡️https://goo.gl/yGVDxE (RSS generated with FetchRss) View the full article
  3. In case you missed the @CBSThisMorning segment on Saturday with Dr. @MarkPochapin, Dr. Seth Gross and @DrLaPook ⬇️ https://twitter.com/AmCollegeGastro/status/1061345134720237570 (RSS generated with FetchRss) View the full article
  4. These prepped carrots from Trader Joe's make roasting carrots just one step easier. Tasty, nutritious and low #FODMAP too. Drizzle with olive oil, season with a little salt+ roast them up. Delicious + EASY #Thanksgiving side dish. (RSS generated with FetchRss) View the full article
  5. Mesenteric vascular and nerve sparing surgery in laparoscopic segmental intestinal resection for deep infiltrating endometriosis. Eur J Obstet Gynecol Reprod Biol. 2018 Nov 01;231:214-219 Authors: Raffaelli R, Garzon S, Baggio S, Genna M, Pomini P, Laganà AS, Ghezzi F, Franchi M Abstract OBJECTIVE(S): To investigate Mesenteric vascular and nerve Sparing Surgery (MSS) as surgical laparoscopic technique to perform segmental intestinal resection for deep infiltrating endometriosis (DIE). STUDY DESIGN: Prospective cohort study between January 2013 and December 2016. Consecutive patients with suspected intestinal DIE underwent clinical and imaging evaluation to confirm intestinal involvement. Indications for radical surgery and surgical technique (intestinal resection versus shaving) were consistent with Abrão algorithm. Surgeons aimed to perform MSS in all the consecutive patients that required intestinal resection. MSS consists in mesenteric artery, branching arteries, and surrounding nerve fibers preservation by dissecting mesentery adherent to the intestinal wall. Data about history, preoperative and post-operative evaluation, surgery and complications were recorded. Symptoms were evaluated before and 30-60 days after surgery with numeric rating scale for pain. Constipation was evaluated with the Constipation Assessment Scale (CAS). Patients with diagnosis of irritable bowel syndrome, inflammatory bowel diseases, diverticulitis, and previous segmental intestinal resection were excluded. RESULTS: Sixty-two out of 75 (82.7%) consecutive women with intestinal endometriosis underwent laparoscopic segmental intestinal resection performed with MSS. Major complications that required repeated operation occurred in 4 cases (6.5%). Anastomotic leakage occurred in only 1 case (1.6%). Dysmenorrhea (p < .001; r = -0.86), dyspareunia (p < .001; r = -0.80), dyschezia (p < .001; r = -0.86) and dysuria (p < .001; r = -0.56) were significantly improved after surgery. After an average of 33.1 months from surgery, severe constipation was reported only by two patients (3.6%) (CAS: 13-16). The median time from surgery to intestinal function recovery (flatus or stool passage) was one day. Logistic regression analysis showed constipation related to the distance from anal verge and time since surgery. CONCLUSION(S): MSS in laparoscopic intestinal resection for DIE may be reproducible, safe and effective. MSS could be combined with pelvic nerve-sparing surgery as an effective approach to improve intestinal symptoms after radical surgery for DIE that requires segmental intestinal resection. PMID: 30415128 [PubMed - as supplied by publisher] View the full article
  6. Studying the #microbiome could be the next frontier in #coloncancer research. Rachel Sarnoff (@RSarnoff) joins CBS Chief Medical Correspondent @DrLaPook to discuss her research, including the study she presented at #ACG2018 ➡️ https://goo.gl/R1QsyJ (RSS generated with FetchRss) View the full article
  7. FUNCTIONAL CONSTIPATION AND OVERACTIVE BLADDER IN WOMEN: A POPULATION-BASED STUDY. UroToday Full coverage View the full article
  8. Yesterday
  9. Fecal Impaction: How to Come Unstuck from an Impacted Bowel Care2.com Full coverage View the full article
  10. Physical Activity, #BMI, and Risk of Fecal Incontinence in the Nurses’ Health Study Read Staller, et al. in Clinical and Translational Gastroenterology ➡️ https://goo.gl/9rv64h #CTGJournal (RSS generated with FetchRss) View the full article
  11. Related Articles Mood Disorders and Gluten: It's Not All in Your Mind! A Systematic Review with Meta-Analysis. Nutrients. 2018 Nov 08;10(11): Authors: Busby E, Bold J, Fellows L, Rostami K Abstract Gluten elimination may represent an effective treatment strategy for mood disorders in individuals with gluten-related disorders. However, the directionality of the relationship remains unclear. We performed a systematic review of prospective studies for effects of gluten on mood symptoms in patients with or without gluten-related disorders. Six electronic databases (CINAHL, PsycINFO, Medline, Web of Science, Scopus and Cochrane Library) were searched, from inception to 8 August 2018, for prospective studies published in English. Meta-analyses with random-effects were performed. Three randomised-controlled trials and 10 longitudinal studies comprising 1139 participants fit the inclusion criteria. A gluten-free diet (GFD) significantly improved pooled depressive symptom scores in GFD-treated patients (Standardised Mean Difference (SMD) -0.37, 95% confidence interval (CI) -0.55 to -0.20; p < 0.0001), with no difference in mean scores between patients and healthy controls after one year (SMD 0.01, 95% CI -0.18 to 0.20, p = 0.94). There was a tendency towards worsening symptoms for non-coeliac gluten sensitive patients during a blinded gluten challenge vs. placebo (SMD 0.21, 95% CI -0.58 to 0.15; p = 0.25). Our review supports the association between mood disorders and gluten intake in susceptible individuals. The effects of a GFD on mood in subjects without gluten-related disorders should be considered in future research. PMID: 30413036 [PubMed - in process] View the full article
  12. Related Articles Exploring the Potential of RET Kinase Inhibition for Irritable Bowel Syndrome: A Preclinical Investigation in Rodent Models of Colonic Hypersensitivity. J Pharmacol Exp Ther. 2018 Nov 09;: Authors: Russell J, Mohammadi E, Ligon CO, Johnson AC, Gershon MD, Rao M, Shen Y, Chan CC, Eidam HS, DeMartino MP, Cheung M, Oliff AI, Kumar S, Greenwood-Van Meerveld B Abstract Abdominal pain represents a significant complaint in patients with irritable bowel syndrome (IBS). While the etiology of IBS is incompletely understood, prior exposure to gastrointestinal (GI) inflammation or psychological stress is frequently associated with the development of symptoms. Inflammation or stress-induced expression of growth factors or cytokines may contribute to the pathophysiology of IBS. Here we aimed to investigate the therapeutic potential of inhibiting the receptor of glial cell line-derived neurotrophic factor (GDNF), rearranged during transfection (RET), in experimental models of inflammation and stress-induced visceral hypersensitivity resembling IBS sequelae. In RetCFP/+ mice, thoracic and lumbosacral dorsal root ganglia (DRG) were shown to express RET and co-localized with calcitonin gene-related peptide (CGRP). To understand the role of RET in visceral nociception, we employed GSK3179106 as a potent, selective, and gut-restricted RET kinase inhibitor. Colonic hyperalgesia quantified as exaggerated visceromotor response (VMR) to graded pressures (0-60 mmHg) of isobaric colorectal distention (CRD) was produced in multiple rat models induced by i) colonic irritation, ii) following acute colonic inflammation, iii) adulthood stress and iv) early life stress. In all the rat models, RET Inhibition with GSK3179106 attenuated the number of abdominal contractions induced by CRD. Our findings identify a role for RET in visceral nociception. Inhibition of RET kinase with a potent, selective, and gut-restricted small molecule may represent a novel therapeutic strategy for the treatment of IBS through the attenuation of post-inflammatory and stress-induced visceral hypersensitivity. PMID: 30413627 [PubMed - as supplied by publisher] View the full article
  13. DR. ISLAM: Don't ignore constipation Odessa American Full coverage View the full article
  14. Last week
  15. RT @LizWeiss: Do you suffer from IBS? TUNE IN to the Liz's Healthy Table #PODCAST for my interview w/ gut health guru @KateScarlata_RD abou… (RSS generated with FetchRss) View the full article
  16. ⭐ RESEARCH UPDATE ⭐ Want to hear more about the new treatments and therapeutic targets for IBS and FBD? Read the new Nature article here: https://go.nature.com/2trZmzX (RSS generated with FetchRss) View the full article
  17. If you are struggling with finding low FODMAP products in the US, Canada and UK, you may want to check out the Fody Food online shop. And if you place an order of at least $75, this week, you will also receive a FREE Fody... https://www.fodyfoods.com/collections/all?aff=66 (RSS generated with FetchRss) View the full article
  18. Related Articles Refractory Irritable Bowel Syndrome and Functional Abdominal Pain Syndrome: Should Small Bowel Endoscopy Be Performed? Clin Endosc. 2018 Nov 09;: Authors: Yim SK, Kim SW PMID: 30408947 [PubMed - as supplied by publisher] View the full article
  19. Related Articles Treatment of irritable bowel syndrome. Aust Prescr. 2018 Oct;41(5):145-149 Authors: Basnayake C Abstract Irritable bowel syndrome is a chronic functional gastrointestinal disorder that presents with abdominal pain related to defecation accompanied by a change in stool frequency or form Despite its impact on a patient’s quality of life it has no effect on mortality: A positive clinical diagnosis should be made if the characteristic symptoms are present and red flags are absent Red flags should prompt specialist referral: Consultations should be provided in an empathetic manner addressing the concerns of the patient while providing reassurance: Manipulating diet with the assistance of a dietitian is an appropriate initial treatment for irritable bowel syndrome A low-FODMAP diet is an effective therapy: PMID: 30410210 [PubMed] View the full article
  20. We have moved to a pretty sterile diet with our desire to have foods with a long shelf life. Should we be getting a daily dose of microbe-rich fermented foods? http://blog.katescarlata.com/2018/11/09/fermented-foods-for-health-fact-vs-fiction/ (RSS generated with FetchRss) View the full article
  21. FREEDOM FOODS ANCIENT GRAIN MUESLI! Made up of delicious high fibre grains like sorghum, millet and quinoa, this muesli is #LowFODMAPCertified and delicious! Eat it plain with your choice of milk or sprinkle on your yoghurt and fruit for a perfect breakfast! (RSS generated with FetchRss) View the full article
  22. VIDEO: Diet low in short-chain carbs helps ease irritable bowel syndrome pain Healio Full coverage View the full article
  23. Changing Beliefs About Emotions in IBS: A Single Case Design. Behav Cogn Psychother. 2018 Nov 08;:1-15 Authors: Bowers HM, Wroe AL Abstract BACKGROUND: Previous research suggests benefits of targeting beliefs about the unacceptability of emotions in treatment for irritable bowel syndrome (IBS). AIMS: The current study developed and tested an intervention focusing on beliefs and behaviours around emotional expression. METHOD: Four participants with IBS attended five group sessions using cognitive behavioural techniques focusing on beliefs about the unacceptability of expressing emotions. Bi-weekly questionnaires were completed and a group interview was conducted. This study used an AB design with four participants. RESULTS: Averages indicate that participants showed decreases in beliefs about unacceptability of emotions and emotional suppression during the intervention, although this was not reflected in any of the individual trends in Beliefs about Emotions Scale scores and was significant in only one individual case for Courtauld Emotional Control Scale scores. Affective distress and quality of life improved during follow-up, with only one participant not improving with regard to distress. Qualitative data suggest that participants felt that the intervention was beneficial, referencing the value in sharing their emotions. CONCLUSIONS: This study suggests the potential for beliefs about emotions and emotional suppression to be addressed in cognitive behavioural interventions in IBS. That beliefs and behaviours improved before outcomes suggests they may be important processes to investigate in treatment for IBS. PMID: 30404677 [PubMed - as supplied by publisher] View the full article
  24. Motility Disorders in Celiac Disease and Non-Celiac Gluten Sensitivity: The Impact of a Gluten-Free Diet. Nutrients. 2018 Nov 07;10(11): Authors: Usai-Satta P, Oppia F, Lai M, Cabras F Abstract Background: There is evidence that digestive motor disorders are frequently present in untreated celiac disease (CD) patients. Similarly, non-celiac gluten sensitivity (NCGS) can be associated with gut motor disorders. In both cases, gut dysmotility can improve or be completely reversed with a gluten-free diet (GFD). Methods: A literature search for motility disorders in CD and NCGS patients was carried out using the online databases PubMed, Medline and Cochrane. Results: Esophageal, gastric, small bowel and gallbladder motor disorders are common in both children and adults with CD. Although the clinical consequences of these disorders are not clearly defined, gastric dysfunction could affect drug absorption and metabolism in the thyroid and neurological conditions associated with CD. The impact of a GFD on motility disorders is, however, controversial. No systematic studies are available on NCGS. NCGS frequently overlaps with irritable bowel syndrome (IBS) and similar pathophysiological mechanisms may be hypothesized. Conclusions: Mucosal damage may affect gut motility in untreated CD through perturbation of hormonal and neuro-immunomodulatory regulation. A persistent low-grade mucosal inflammation could explain the cases of persistent motor disorders despite a GFD. Further studies are needed to definitely assess the role of gut motor disorders in NCGS. PMID: 30405092 [PubMed - in process] View the full article
  25. The Human Gut Colonizer Blastocystis Respires Using Complex II and Alternative Oxidase to Buffer Transient Oxygen Fluctuations in the Gut. Front Cell Infect Microbiol. 2018;8:371 Authors: Tsaousis AD, Hamblin KA, Elliott CR, Young L, Rosell-Hidalgo A, Gourlay CW, Moore AL, van der Giezen M Abstract Blastocystis is the most common eukaryotic microbe in the human gut. It is linked to irritable bowel syndrome (IBS), but its role in disease has been contested considering its widespread nature. This organism is well-adapted to its anoxic niche and lacks typical eukaryotic features, such as a cytochrome-driven mitochondrial electron transport. Although generally considered a strict or obligate anaerobe, its genome encodes an alternative oxidase. Alternative oxidases are energetically wasteful enzymes as they are non-protonmotive and energy is liberated in heat, but they are considered to be involved in oxidative stress protective mechanisms. Our results demonstrate that the Blastocystis cells themselves respire oxygen via this alternative oxidase thereby casting doubt on its strict anaerobic nature. Inhibition experiments using alternative oxidase and Complex II specific inhibitors clearly demonstrate their role in cellular respiration. We postulate that the alternative oxidase in Blastocystis is used to buffer transient oxygen fluctuations in the gut and that it likely is a common colonizer of the human gut and not causally involved in IBS. Additionally the alternative oxidase could act as a protective mechanism in a dysbiotic gut and thereby explain the absence of Blastocystis in established IBS environments. PMID: 30406045 [PubMed - in process] View the full article
  26. A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and accelerating colon transit: A pilot study. Indian J Gastroenterol. 2018 Nov 08;: Authors: Ghoshal UC, Srivastava D, Misra A Abstract OBJECTIVE: Gut microbe-derived methane may slow colon transit causing chronic constipation (CC). Effect of rifaximin on breath methane and slow-transit CC was evaluated. METHOD: Bristol stool form, frequency, colon transit time (CTT), and breath methane were evaluated in 23 patients with CC (10 patients with constipation-predominant irritable bowel syndrome [IBS-C], 13 functional constipation, Rome III) and m-ethane production compared with 68 non-constipating IBS. Methane-producing CC (basal ≥ 10 PPM and/or post-lactulose rise by > 10 PPM) was randomized (double-blind) to rifaximin (400-mg thrice/day, 2-weeks) or placebo. Stool forms, frequency, breath methane, and CTT were recorded afterward. RESULTS: CC patients tended to be methane producer more often (13/23 [56.5%] vs. 25/68 [36.5%], p = 0.07) and had greater area under curve (AUC) for methane (2415 [435-23,580] vs. 1335 [0-6562.5], p = 0.02) than non-constipating IBS. Methane producers (8/13 [61.5%]) and 5/10 (50%) non-producers had abnormal CTT (marker retention: 36-h, 53 [0-60] vs. 19 [8-56], p = 0.06; 60-h, 16 [0-57] vs. 13 [3-56], p = 0.877). Six and 7/13 methane producers were randomized to rifaximin and placebo, respectively. Rifaximin reduced AUC for methane more (6697.5 [1777.5-23,580] vs. 2617.5 [562.5-19,867.5], p = 0.005) than placebo (3945 [2415-12,952.5] vs. 3720 [502.5-9210], p = 0.118) at 1 month. CTT normalized in 4/6 (66.7%) on rifaximin (36-h retention, 54 [44-57] vs. 36 [23-60], p = 0.05; 60-h, 45 [3-57] vs. 14 [11-51], p = 0.09) but none on placebo (p = 0.02) (36-h, 31 [0-60] vs. 25 [0-45], p = 0.078; 60-h, 6 [0-54] vs. 12 [0-28], p = 0.2). Weekly stool frequency (3 [1-9] and 7 [1-14], p = 0.05) and forms improved with rifaximin than placebo. CONCLUSION: Rifaximin improves CC by altering methane production and colon transit. TRIAL REGISTRATION: Clinical Trial Registry, India: REF/2012/01/003216 ᅟ ᅟ. PMID: 30406392 [PubMed - as supplied by publisher] View the full article
  27. Irritable bowel syndrome and colonic diverticular disease: overlapping symptoms and overlapping therapeutic approaches. Curr Opin Gastroenterol. 2018 Nov 06;: Authors: Alamo RZ, Quigley EMM Abstract PURPOSE OF REVIEW: Irritable bowel syndrome (IBS) is a common symptomatic disorder in the Western world and colonic diverticula are also prevalent; however, relationships between IBS-type symptoms and diverticula have been a source of much debate. Our goal was to reassess these relationships in the light of new data. RECENT FINDINGS: On removing from consideration clinical scenarios which are directly related to diverticula (i.e., diverticulitis, diverticular hemorrhage, and complications of diverticulitis, such as stricture and fistula), relationships between IBS and diverticula can be seen to revolve around a number of questions. First, are IBS and symptomatic uncomplicated diverticular disease (SUDD) the same condition? Or, in other words is SUDD no more than IBS in an individual who just happens to have diverticula? Although coincident IBS and diverticula inevitably do occur there is some evidence to indicate that SUDD may be somewhat distinctive with SUDD being characterized by more frequent and severe pain. Second, and analogous to interactions between IBS and inflammatory bowel disease or celiac disease, can an episode of acute diverticulitis lead to the de novo development of IBS? There is now epidemiological and pathophysiological evidence to support this occurrence. SUMMARY: Although relationships between uncomplicated diverticular disease and IBS have been reexamined their status remains unclear. As yet, however, none of the newer concepts related to this relationship have led to new therapeutic approaches in IBS or diverticular disease. PMID: 30407258 [PubMed - as supplied by publisher] View the full article
  28. Excluding irritable bowel syndrome in the inflammatory bowel disease patient: how far to go? Curr Opin Gastroenterol. 2018 Nov 06;: Authors: Nemakayala DR, Cash BD Abstract PURPOSE OF REVIEW: Irritable bowel syndrome (IBS) is among the most commonly encountered conditions in primary care and gastroenterology. There is ample evidence that an IBS diagnosis based on symptom-based criteria and exclusion of alarm features that would otherwise support diagnostic testing is accurate and durable. For many clinicians, however, IBS remains a diagnosis of exclusion because of concern surrounding missed diagnoses of inflammatory bowel disease (IBD) or other organic gastrointestinal diseases. Using blood and/or fecal biomarker tests to shift the precolonoscopy probability of IBD in patients with symptoms mimicking IBS is becoming an increasingly reasonable practice with improvement in 'preliminary' tests. RECENT FINDINGS: Fecal calprotectin (FCP) testing appears to be the most sensitive preliminary test for discriminating IBD from IBS. Although both fecal lactoferrin and FCP were superior to serum C-reactive peptide (CRP) in their diagnostic accuracy, FCP is superior to fecal lactoferrin based on available literature. SUMMARY: In patients with IBS with diarrhea who have not undergone previous extensive evaluation, the ability of screening tests to detect colonic inflammation is improving. FCP and fecal lactoferrin are reliable predictors of colonic inflammation and should be considered for standard testing in patients with IBS-D symptoms to help identify those who would benefit most from colonoscopy. Although predictive, there currently are no fecal or serum tests that can definitively identify or subtype IBD. PMID: 30407259 [PubMed - as supplied by publisher] View the full article
  29. Load more activity